Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Similar articles for PubMed (Select 21716715)

2.

Evaluating Immune Responses After Sipuleucel-T Therapy.

Strauss J, Madan RA, Figg WD.

Cancer Biol Ther. 2015 Jun 8:0. [Epub ahead of print]

PMID:
26054644
3.

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.

Mulders PF, De Santis M, Powles T, Fizazi K.

Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30.

4.

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

Davis K, Wood S, Dill E, Yuri Fesko YF, Bitting RL, Harrison MR, Armstrong AJ, Moul JW, George DJ.

Clin J Oncol Nurs. 2015 Jun 1;19(3):297-303. doi: 10.1188/15.CJON.297-303.

PMID:
26000580
5.

Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.

Slovin SF.

Am Soc Clin Oncol Educ Book. 2015;35:e275-83. doi: 10.14694/EdBook_AM.2015.35.e275.

7.

Survival Outcomes of Sipuleucel-T Phase 3 Studies: Impact of Control Arm Cross-over to Salvage Immunotherapy.

George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.

Cancer Immunol Res. 2015 May 5. pii: canimm.0006.2015. [Epub ahead of print]

PMID:
25943532
8.

Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.

McNamara M, Berry W.

Clin Genitourin Cancer. 2015 Feb 7. pii: S1558-7673(15)00018-X. doi: 10.1016/j.clgc.2015.02.004. [Epub ahead of print] No abstract available.

PMID:
25735199
9.

Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC.

Sidaway P.

Nat Rev Urol. 2015 Apr;12(4):181. doi: 10.1038/nrurol.2015.33. Epub 2015 Feb 24. No abstract available.

PMID:
25708576
10.

HUMORAL IMMUNE RESPONSE AGAINST NON-TARGETED TUMOR ANTIGENS AFTER TREATMENT WITH SIPULEUCEL-T AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME.

GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, Kantoff P, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG.

Clin Cancer Res. 2015 Feb 3. pii: clincanres.2334.2014. [Epub ahead of print]

PMID:
25649018
11.

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.

Graff JN, Chamberlain ED.

Core Evid. 2014 Dec 18;10:1-10. doi: 10.2147/CE.S54712. eCollection 2015. Review.

12.

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Mouraviev V, Mariados N, Albala D, Concepcion RS, Shore ND, Sims RB, Emberton M, Pieczonka CM.

Rev Urol. 2014;16(3):122-30. Review.

13.

Metastatic castrate-resistant prostate cancer.

Schellhammer P.

Urol Oncol. 2015 Jan;33(1):51-2. doi: 10.1016/j.urolonc.2014.07.006. Epub 2014 Sep 3. No abstract available.

PMID:
25192835
14.

A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R.

Cancer Immunol Res. 2014 Oct;2(10):988-99. doi: 10.1158/2326-6066.CIR-14-0073. Epub 2014 Sep 4.

PMID:
25189164
15.

Embelin, a small molecule quinone with a co-clinical power for castrate-resistant prostate cancer.

Poojari RJ.

Front Pharmacol. 2014 Aug 8;5:184. doi: 10.3389/fphar.2014.00184. eCollection 2014. No abstract available.

16.

Sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) patients ≥80 years-old: data from PROCEED.

[No authors listed]

Clin Adv Hematol Oncol. 2014 Apr;12(4 Suppl 11):11. No abstract available.

PMID:
24870259
17.

Impact of prior radiation treatment (tx) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts).

[No authors listed]

Clin Adv Hematol Oncol. 2014 Apr;12(4 Suppl 11):8. No abstract available.

PMID:
24870257
18.

Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer.

[No authors listed]

Clin Adv Hematol Oncol. 2014 Apr;12(4 Suppl 11):4-5. No abstract available.

PMID:
24870255
19.

Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?

Mottet N, Clarke N, De Santis M, Zattoni F, Morote J, Joniau S.

BJU Int. 2015 Mar;115(3):364-72. doi: 10.1111/bju.12736. Epub 2014 Jul 15.

PMID:
24628790
20.

Sipuleucel-T and immunotherapy in the treatment of prostate cancer.

Dawson NA, Roesch EE.

Expert Opin Biol Ther. 2014 May;14(5):709-19. doi: 10.1517/14712598.2014.896897. Epub 2014 Mar 12.

PMID:
24620782
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk